% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Weller:309607,
author = {J. Weller and D. Harba and L. Kuschel and F. Thiele and S.
Katzendobler and A. Corell and A. Dénes and M.
Schmutzer-Sondergeld and E. de Dios and F. Ringel and J. C.
Tonn$^*$ and A. S. Jakola},
title = {{A}ssociation of a diffuse phenotype on {MRI} with shorter
overall survival in patients with astrocytoma {CNS} {WHO}
grades 2 and 3.},
journal = {Journal of neurosurgery},
volume = {nn},
issn = {0022-3085},
address = {Charlottesville, Va.},
publisher = {American Assoc. of Neurological Surgeons},
reportid = {DKFZ-2026-00257},
pages = {nn},
year = {2026},
note = {#DKTKZFB9# / epub},
abstract = {Gliomas can appear radiologically diffuse or sharply
delineated on MRI. This can be quantified by the T1/T2
ratio, a quotient of the T1 hypointense to T2 hyperintense
tumor volume. In patients with CNS WHO grade 2 and 3
isocitrate dehydrogenase (IDH)-mutant astrocytomas,
resectability has been shown to be limited in cases of low
T1/T2 ratios, that is, in diffusely appearing astrocytomas.
The authors set out to investigate if a diffuse phenotype on
MRI is associated with overall survival beyond
resectability.Retrospective data sets from two university
hospitals (Sahlgrenska University Hospital, Gothenburg,
Sweden; LMU University Hospital, Munich, Germany) were
screened for patients diagnosed with 2021 CNS WHO grade 2
and 3 astrocytomas by biopsy between 2003 and 2021. Patients
having undergone tumor resection were excluded. Tumor
volumes were segmented and the T1/T2 ratio was calculated.
Propensity score matching (nearest-neighbor matching, 1:1)
was used.One hundred nineteen patients with CNS WHO grade 2
(n = 77, $65\%)$ or grade 3 (n = 42, $35\%)$ IDH-mutant
astrocytomas were included in the study. In unadjusted
analyses, survival was not significantly shorter in patients
with a T1/T2 ratio ≤ 0.33 (144 vs 126 months; HR 0.61,
$95\%$ CI 0.34-1.1; p = 0.09). Propensity score matching
(Karnofsky Performance Status, CNS WHO 2021 grade, contrast
enhancement on MRI, and T2 tumor volume) yielded 29 pairs.
Here, significantly shorter overall survival was observed in
patients with a T1/T2 ratio ≤ 0.33 (160 vs 132 months; HR
0.44, $95\%$ CI 0.19-1.00; p = 0.05). In multivariate
analysis, only the T1/T2 ratio persisted as a prognostic
factor (HR 0.48, $95\%$ CI 0.25-0.92; p = 0.03).A diffuse
phenotype on MRI seems to be associated with shorter
survival times in patients with CNS WHO grade 2 and 3
astrocytomas. These findings warrant further investigation
in prospective data sets.},
keywords = {IDH mutation (Other) / biopsy (Other) / diagnostic
technique (Other) / low-grade glioma (Other) / oncology
(Other) / prognosis (Other) / risk factor (Other) / tumor
volume (Other)},
cin = {MU01},
ddc = {610},
cid = {I:(DE-He78)MU01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41616295},
doi = {10.3171/2025.9.JNS251254},
url = {https://inrepo02.dkfz.de/record/309607},
}